NCT06744361

Ketamine Sedation As Neuroprotective Agent Following Out-of-hospital Cardiac Arrest

KETamine Sedation As Neuroprotective Agent Following Out-of-hospital Cardiac Arrest (OHCA) - the KETOHCA Trial

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 282 (estimated)
• Sponsor: Christian Hassager · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

OHCA is a critical medical emergency with significant mortality and morbidity primarily due to hypoxic-ischemic brain injury (HIBI). Despite advances in resuscitation techniques, the neurological outcomes for survivors remain poor. Current post-resuscitation practices lack specific neuroprotective strategies. Ketamine, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, has shown potential neuroprotective properties in preclinical and clinical studies due to its ability to inhibit excitotoxicity and reduce neuronal apoptosis. This trial hypothesizes that ketamine, when used for sedation in OHCA patients, may offer superior neuroprotective benefits compared to the commonly used sedative propofol. By comparing the effects of ketamine and propofol on neuronal damage markers and long-term neurological outcomes, this study aims to identify a potentially effective intervention to improve the prognosis of OHCA patients.

Conditions

• Out-of-hospital Cardiac Arrest (OHCA)

Interventions

Type	Name	Description
DRUG	esketamine hydrochloride	Prehospital intravenous or intraosseous bolus administration at a minimum of 0.5 mg/kg of esketamine
DRUG	propofol	Prehospital intravenous or intraosseous bolus administration at a minimum dose of 0.25 mg/kg propofol

Timeline

• Start date: 2024-12-12
• Primary completion: 2027-09-01
• Completion: 2027-09-01
• First posted: 2024-12-20
• Last updated: 2024-12-20

Locations

2 sites across 1 country: Denmark